Summary

The age-adjusted incidence of a new diagnosis of heart failure (HF) has not changed over the past decades and, in some patient populations, is actually decreasing. However, because our society is aging and mortality from HF has been reduced, the prevalence of people living with a diagnosis of HF has increased and is currently fueling a cycle of hospitalization for HF. This article discusses the impact of HF drugs in patients with diabetes, the impact of new glucose-lowering drugs on HF, sodium glucose cotransporter 2 (SGLT-2) inhibitors.